trial
as of 2026-07-01Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
NCTId NCT00968851
at a glance
Phase 2 · Completed
Enrollment 317 (actual)
Sponsored by FORUM Pharmaceuticals Inc
Primary completion 2011-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
317 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-12
Primary completion
2011-01
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
FORUM Pharmaceuticals IncLead Sponsor
Syneos HealthCollaborator
Investigators
1
Chris SouthardStudy Director
Sites
17 total
Glendale, United StatesOceanside, United StatesSan Diego, United StatesSan Diego, United StatesSherman Oaks, United StatesNorth Miami, United StatesChicago, United StatesHoffman Estates, United StatesRockville, United StatesWillingboro, United StatesCharleston, United StatesNashville, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
317
Phase
PHASE2
Primary Completion Date
2011-01
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
investigator
person